{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Diagnosis and Main Eligibility Criteria', 'This study will include males with severe hemophilia A or B without inhibitors (defined as Nijmegen', 'modified Bethesda assay inhibitor titer of <0.6 BU/mL at Screening), aged >12 years, who have had a', 'minimum of 6 bleeding episodes requiring on-demand treatment with factor concentrates within the', 'last 6 months prior to Screening. Diagnosis of severe hemophilia A or B will be based on a central', 'laboratory measurement or documented medical record evidence of FVIII level <1% or FIX level 2%.', 'Investigational Product, Dose and Mode of Administration', 'Fitusiran is an SC administered N-Acetylgalactosamine (GalNAc)-conjugated siRNA targeting liver-', 'expressed messenger RNA (mRNA) for AT.', 'Patients randomized to the fitusiran treatment arm will receive open-label fitusiran 80 mg as an SC', 'injection once monthly for a total of 9 months; dosing will begin on Day 1 of the treatment period.', 'Reference Therapy, Dose and Mode of Administration', 'Patients in the on-demand arm will receive on-demand factor concentrate therapy per Investigator', 'discretion to treat bleeding episodes from Day 1 through end of study. The protocol will recommend', 'guidance for patients in the fitusiran treatment arm to use reduced initial doses of factor concentrates', 'for breakthrough bleeding episodes during the fitusiran efficacy period.', 'Duration of Treatment', 'The duration of treatment with fitusiran is 9 months. The estimated total time on study, inclusive of', 'screening, for each patient is up to 11 months for all patients who enroll in the extension study and', 'patients in the on-demand arm who do not enroll in the extension study. The estimated total time on', 'study may be up to 17 months in fitusiran treatment arm patients who do not enroll in the extension', 'study due to the requirement for an additional 6 months of follow-up for monitoring of AT levels.', 'Statistical Methods', 'Sample Size Calculation', 'Assuming a mean ABR of 18 with standard deviation (SD) = 14 in the on-demand arm (patients', 'randomized to receive only factor concentrates) and a mean ABR of no more than 4 with SD = 6 in the', 'fitusiran treatment arm (patients randomized to receive fitusiran) in either the efficacy period or', 'treatment period, with a sample size of 32 evaluable patients in the on-demand arm and approximately', '64 evaluable patients in the fitusiran treatment arm, it is projected that the study will have greater than', '90% power for detecting treatment difference in mean ABRs. This power estimation was based on a', 'negative binomial regression model with a 2-sided type I error rate of 0.05.', 'The planned sample size is 120 randomized patients assuming a 20% drop-out rate.', 'Analyses', 'The primary analysis will be performed on the intent-to-treat (ITT) analysis set which includes all', 'randomized patients. The primary endpoint will be based on the bleeding episodes occurring in the', 'efficacy period (Day 29 to Day 246) including the data collected after discontinuation of', 'investigational medicinal product (IMP). To avoid confounding the treatment effect, bleeding data', 'during and after major surgery, antithrombin (AT) administration, major trauma, or after initiation of', 'prophylaxis treatment with factor concentrates will be excluded from the primary analysis.', 'The number of bleeding episodes will be analyzed using a negative binomial model with fixed effects', 'of treatment arm, the number of bleeding episodes in the 6 months prior to study entry (10 vs >10),', 'and hemophilia type (hemophilia A or B). The logarithm number of days that each patient spends in', 'the efficacy period matching the bleeding episode data being analyzed will be included as an offset', 'Property of the Sanofi Group - strictly confidential', '9', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'variable to account for unequal follow-up time due to early withdrawal or surgery. The ratio of the', 'bleeding rate on the fitusiran treatment arm relative to the bleeding rate on the on-demand arm and its', '95% confidence interval will be presented. Sensitivity analyses will be performed to evaluate the', 'impact of missing data under different missing data mechanisms and details will be specified in the', 'statistical analysis plan.', 'The bleeding episodes in the treatment period (Day 1 to Day 246), spontaneous bleeding episodes in', 'the efficacy period, joint bleeding episodes in efficacy period, and bleeding episodes in the onset period', 'will be analyzed and compared using the same model as used in the primary analysis. The change from', 'baseline in physical health score and total score of Haem-A-QOI will be analyzed using an analysis of', 'covariance (ANCOVA) model with fixed effects of treatment arm, baseline Haem-A-QOL physical', 'health score and total score, the number of bleeding episodes in the 6 months prior to study entry (10', 'VS >10), and hemophilia type (hemophilia A or B) as covariates.', 'Familywise error rate will be strongly controlled for the primary endpoint and selected secondary', 'endpoints using a fixed sequence testing procedure.', 'Safety results will be summarized descriptively.', 'Property of the Sanofi Group - strictly confidential', '10', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}